News & Events

Here is what is going on

16APR 2019

2nd AMP Global 2019 Congress on Molecular Pathology: Evidence-based Precision Medicine

Hong Kong, AsiaWorld-Expo 16.-18. Mai 2019

Visit our booth No 27

27APR 2019

ESMO 2019 Congress: Translating science into better cancer patient care​

Barcelona, Spain, Fira Gran Via, 27.09.-01.10.2019

Visit our booth

07APR 2019

Molecular Health Licenses its Proprietary Predictive Analytics to DATEN CAPITAL

Molecular Health Predict enables highly accurate estimates of clinical trial success probabilities
• Exclusive license for the financial industry granted to DATEN CAPITAL
• Molecular Health to receive an annual license fee and success-based payments

Heidelberg, Germany and Boston, MA — Monday, January 7, 2019 — Molecular Health, a leading company in the field of data science for precision medicine and specializing in the development of products and services leveraging its proprietary biomedicine technology platform Dataome®, is pleased to announce that it has granted an exclusive license for Molecular Health Predict (MH Predict) to DATEN CAPITAL LLP (DATEN), for its use in the financial industry. MH Predict was developed by Molecular Health to calculate the likelihood of success of drug clinical trials, and DATEN is a private limited liability partnership founded to commercialize data-science, AI-driven approaches to investing. Molecular Health will receive an annual license fee as well as success-based payments from DATEN.

Friedrich von Bohlen, PhD, Cofounder & CEO of Molecular Health GmbH, said: “We are very excited to announce this exclusive license for the financial industry with DATEN CAPITAL. Understanding and effectively predicting the likelihood of success of clinical trials is critical to achieving better efficiencies and savings in drug R&D – which today still represents billions of dollars of annual losses due to trial attrition for both pharmaceutical companies and investors. We believe that MH Predict will drive a true paradigm shift in drug development, resource and investment allocations and ultimately patient outcomes. We look forward to launching this product also to the pharmaceutical industry in early 2019.”

“I came to know Friedrich von Bohlen and Molecular Health during my time in investment banking at Goldman Sachs. After learning more about the company, and assessing its technology, I became increasingly convinced of the potential for Molecular Health to transform the drug development industry. Our mission when founding DATEN CAPITAL was to build a data-science, AI-driven approach to allocating capital. This is why we are particularly excited to have obtained an exclusive license to apply MH Predict to the financial markets. Our aim, and our belief, is that we will help enable the biopharmaceutical industry to deliver new drugs to the market in a much better, faster and cheaper way,” said Amit R. Karna, CFA, Managing Partner at DATEN CAPITAL LLP.

About MH Predict
MH Predict is an artificial intelligence (AI) based product that predicts the likelihood of success of a clinical trial to achieve its endpoints. Models are designed and validated based on a range of public and proprietary data sources, including Dataome®, a proprietary database custom built by Molecular Health over 10 years and with over €150m of invested capital.

About Molecular Health
Molecular Health is a data science-focused artificial intelligence computing company enabling and improving decision making in precision medicine for healthcare organizations. The company offerings are based on the capture, curation, integration, and analysis of large biomedical and drug data sets and combining them with novel artificial intelligence and machine learning (AI/ML) technologies. For more than a decade, the company has been developing Dataome®, a unique high-quality curated, interoperable system that combines clinico-molecular and drug data with proprietary analytical processes. Dataome® – stand alone or in combination with customer data – enables the unlocking of actionable intelligence at the molecular level to a) improve diagnosis and therapy decisions by physicians and patients; b) enrich and support better drug discovery, drug development, trial optimization, drug differentiation and positioning for pharma and healthcare organizations; and c) more accurately predict the likelihood of success and likelihood of approval of drug candidates in clinical development for better trial prioritization and resource and investment allocation.
For more information, visit

DATEN CAPITAL LLP (DATEN) is a private limited liability partnership incorporated in England and Wales (registered no: OC424550). The firm was founded in 2018 with a mission to apply data-science, AI-driven solutions to the financial markets. DATEN plans to initially focus on the biotech sector, primarily in the US and Europe. The Managing Partner for DATEN is Amit R. Karna, CFA, a former investment banker who spent ten years in the healthcare team at Goldman, Sachs & Co., based initially in New York before transferring to London. DATEN CAPITAL LLP is backed by leading investors and individuals in the healthcare and technology sectors.
For more information, visit

06APR 2019

Molecular Health plenary session at BPMS 2018: “Exploiting AI: From Discovery to Treatment”

While realizing the enormous potential of personalized medicine has turned out to be neither quick nor easy, recent scientific and technological progress has been impressive, pointing to a possible tipping point. The 5th Annual Business of Personalized Medicine Summit will bring together top executives from across multiple stakeholder perspectives for a look at the state of the industry past, present, and future. Through a series of thought-provoking discussions, the 2018 Summit will:

– Explore solutions to the obstacles and limitations that have kept us from realizing the full promise of personalized medicine to date, as well as emerging challenges we must overcome to continue advancing medicine and the marketplace

– Celebrate the extraordinary achievements in innovation and collaboration that have led us to where we are now while looking ahead to promising new advances underway

– Examine the complexities, trends, and opportunities of an evolving personalized medicine landscape driven by the convergence of science and technology, including implications for the future of business and policy in the field

Global Head of Pharma & Biotech Blanca Baez speaks on “Exploiting AI: From Discovery to Treatment” in a plenary session in South San Francisco, CA on Thursday, December 6, 10:50 AM – 11:40 AM.

The Westin San Francisco Airport
1 Old Bayshore Highway
Millbrae, CA 94030

05APR 2019

Molecular Health To Attend Key Events and Scientific Conferences In The Third Quarter 2018

Molecular Health announced that the company is going to attend several industry and scientific conferences in the third quarter 2018.

The 16th Annual Meeting of Japanese Society of Medical Oncology JSMO, July 19 – 21, 2018 – Kobe International Conference Center, Japan. Attendance: 3 posters and 1 oral presentation
– MH BRCA – Confident BRCA1/2 variant classification: using ACMG and public data for systematic molecular profiling
– Intelligent treatment decision support combining variant interpretation and phenotype analytics can transform healthcare
– Comprehensive treatment decision support of more than 1,000 patients by the medical device Molecular Health Guide®
– Evidence-based software for NGS in pancreatic cancer: first results from the PePaCaKa study

The 9th Annual Cancer Genomics Consortium CGC Meeting, August 6 – 8, 2018 – Nashville, TN, USA. Attendance: Molecular Health booth.

Molekularpathologie-Symposium, September 5-9, Gera, Germany. Attendance: lecture from Dr. Stephan Brock CTO of Molecular Health.
Heidelberger Myelomtage, September 21 – 23, 2018 – Im Neuenheimer Feld 410, 69120 Heidelberg, Germany. Attendance: Molecular Health booth.
ISPOR Asia Pacific 2018, September 8 – 11, 2018 – Kei Plaza Hotel, Tokyo, Japan. Attendance: Poster presentation.
– MH EFFECT® – A novel technology for the molecular analyses of real world outcomes/adverse event data.

08APR 2019

Molecular Health launches MH Mendel for the genetic diagnosis of hereditary diseases

MH Mendel combines the most relevant information for the diagnosis of hereditary diseases

It helps patients and supports physicians through most modern and comprehensive precision medicine technologies and expertise

MH Mendel becomes an integral part of IVD registered Molecular Health Guide® 3.0

Heidelberg, Germany and Boston, USA – June 8, 2018 – Molecular Health (MH), a leading biomedical company that is transforming molecular data into clinically actionable information for efficient and safer cancer treatment options based on its proprietary Dataome® technology platform, has introduced Molecular Health Guide® Mendel (MH Mendel) as part of the established Molecular Health Guide® (MH Guide), a comprehensive software solution for precision medicine. MH Mendel, an integral part of the MH Guide 3.0, a registered IVD product, supports human geneticists in creating a diagnostic report based on their own variant classifications. MH Mendel combines the information that is most relevant for the diagnosis of hereditary diseases.

Data from a variety of sources are provided to help human geneticists to assess and classify variants detected in their patients. MH Mendel includes population frequencies, reported clinical significance, and functional impact predictions for a plethora of variants. For analysis of germline variants associated with hereditary diseases, MH Mendel supports human geneticists in managing their own variant classifications and interpretations as well as in creating diagnostic reports.

“Genetic tests can reveal a predisposition to rare hereditary diseases. Today some hereditary diseases can be managed. Early detection and precise understanding is important to initiate treatment and to prevent avoidable irreparable defects. Results of genetic tests analyzed and evaluated by MH Mendel can reveal ae predisposition to diseases and help physicians to find the exact molecular cause and to create a personalized diagnostic report for each patient “, says Dr. Stephan Brock, CTO of Molecular Health. “We are glad that with MH Mendel we can now help patients and support physicians with our advanced and highly curated and integrated precision medicine technologies and expertise.”

01APR 2019

Molecular Health launches MH Guide 3.0 – New features for intuitive biomarker classification and improved usability

New features for intuitive biomarker classification and improved usability

Heidelberg, Germany and Boston, USA – June 1, 2018 – Molecular Health (MH), a leading company in the field of precision medicine, specialized in the development of products and services leveraging their proprietary Dataome® technology platform, has launched Version 3.0 of Molecular Health Guide® (MH Guide), a comprehensive software solution for precision medicine. MH Guide compares patient-specific molecular information with biomedical knowledge to deliver an interactive, editable, medical report that supports treating physicians in evaluating the range of therapy options identified for the unique genomic profile of the patient. MH Guide is registered as an in vitro diagnostic device in the EU.

Physicians need to understand and interpret numerous biomarkers to assess their significance and make a reliable statement on the suitability of a specific cancer therapy. MH Guide identifies clinically significant variants from panel or whole exome analyses and provides physician-approved variant interpretations describing their clinical significance in the context of the patient’s disease. Physicians use this expert-curated knowledge on each variant and follow clickable references to the peer-reviewed sources as a basis for their clinical reports.

Version 3.0 comes with an improved AMP guideline-compliant biomarker classification scheme and supports HGVS variant nomenclature. MH Guide 3.0 users can now incorporate results from other important diagnostic tests in their reports, such as protein expression, mutational burden, and microsatellite instability. Customizable gene filters mean physicians can streamline the workflow to focus on standard panels for genes of interest. Variant details from standard sources recommended by variant classification guidelines are now shown in MH Guide, in addition to the physician-approved variant interpretations, to support the physician in assessing the clinical significance of a variant. The MH Order portal provides order management tools for seamless communication between labs, hospitals, and Molecular Health.

“MH Guide 3.0 marks a further milestone in cancer treatment based on the genetic variants in a tumor. It gives the treating oncologist a fast and comprehensive overview of treatment recommendations,” said Dr. Rudolf Caspary, CIO of Molecular Health. “We can help to significantly facilitate and improve the daily clinical routine of the treating physicians, while delivering well-informed therapy decisions. Ultimately, this benefits patients – and the entire healthcare system.”

Prof. Dr. Matthias Löhr, Professor of Gastroenterology at the Karolinska Institutet in Stockholm, commented “As longstanding users of MH Guide we are especially impressed by the quality of the results and their clear presentation in version 3.0 of MH Guide. This makes MH Guide easy to use and easy to integrate in our daily routine. We can focus on the essentials – making informed decisions on the best therapy available and the best care for each individual patient.”